Hemosol gears up to test blood substitute product

Article Abstract:

Hemosol Inc. (Toronto) is preparing to begin testing its Hemolink blood substitute product to treat acute anemia. Acute anemia is caused when red blood cells are lost because of active bleeding during cardiac and orthopedic surgery or during treatments such as chemotherapy for cancer. Hemosol has completed Phase III clinical trials of Hemolink with cardiac bypass surgery patients in Canada and the UK, and expects to report trial results next month. Hemosol is now conducting Phase III cardiac bypass trial in the US and expects the trial to be completed in the first quarter of next year, clearing the way for a marketing application and potential approval in early 2002. Human testing with Hemolink to treat chemotherapy-induced anemia is scheduled to begin in the third quarter of this year. Hemosol president and CEO John Kennedy estimated the annual cardiac surgery market in North America alone at about 1.5 million units of Hemolink, which would be worth $750-million (US).

Science & research, Biological Products

---

Hemosol shares jump on deal with U.S. company

Article Abstract:

Toronto, Ont.-based Hemosol Inc. has signed a long-term contract with Pennsylvania Plasma, which is owned by North Brunswick, NJ-based Sera-Tec Biologicals. Hemosol, which is a biotechnology firm, will use blood supplied by Pennsylvania Plasma to make its Hemolink blood substitute product.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Use of services, New orders received, Blood Plasma & Products, Management, Drugs, Finance, Contracts, Sera-Tec Biologicals, Pennsylvania Plasma

---

Hemosol revisits blood substitute

Article Abstract:

An independent safety review committee has recommended that Hemosol Inc. conduct further clinical testing of its blood substitute product. Hemosol reported that a high incidence of heart damage occurred in an initial study of patients undergoing cardiac bypass surgery.

Product development, Synthetic Blood, Blood substitutes

Similar abstracts:

• Abstracts: Free papers to do battle in Toronto. Krispy Kreme Doughnuts prepares to roll into Canada. Krispy Kreme doughnuts expanding to Eastern Canada
• Abstracts: Brokerages post record profits. Disney survives Pearl Harbor. Brokerage industry on a record run
• Abstracts: Corel returns to profitability. Tundra tumbles 18% on reduced sales guidance
• Abstracts: Sumitomo Metal to buy stake in Teck. Rio Algom profit drops sharply in 1998 on low commodity prices
• Abstracts: Dorel struggles to build following. Dorel in deal to buy Safety 1st. Spinoffs not guaranteed an easier road ahead

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.